[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100542509":3},{"organization":4,"armGroups":7,"interventions":38,"overallOfficials":44,"centralContacts":45,"locations":51,"responsibleParty":158,"collaborators":160,"id":164,"slug":165,"hasResults":166,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":170,"eligibilityCriteria":171,"healthyVolunteers":166,"sex":172,"minAge":173,"maxAge":44,"enrollmentInfo":174,"targetDuration":44,"studyType":177,"phases":178,"briefSummary":180,"conditions":181,"keywords":44,"overallStatus":116,"whyStopped":44,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":192},{"fullName":5,"class":6},"ReAlta Life Sciences, Inc.","INDUSTRY",[8,14,18,22,26,30,34],{"label":9,"type":10,"description":11,"interventionNames":12},"RLS-0071Cohort 1","EXPERIMENTAL","10 mg\u002Fkg Q8H RLS-0071 for 7 days",[13],"Drug: RLS-0071",{"label":15,"type":10,"description":16,"interventionNames":17},"RLS-0071 Cohort 2","10 mg\u002Fkg Q8H RLS-0071 for 14 days with concurrent ruxolitinib",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"RLS-0071 Cohort 3","20 mg\u002Fkg Q8H RLS-0071 for 14 days with concurrent ruxolitinib",[13],{"label":23,"type":10,"description":24,"interventionNames":25},"RLS-0071 Cohort 4","10 mg\u002Fkg Q8H RLS-0071 for 7 days and then 10 mg\u002Fkg QD RLS-0071 for 7 days with concurrent ruxolitinib",[13],{"label":27,"type":10,"description":28,"interventionNames":29},"RLS-0071 Cohort 5","20 mg\u002Fkg Q8H RLS-0071 for 7 days and then 20 mg\u002Fkg QD RLS-0071 for 7 days with concurrent ruxolitinib",[13],{"label":31,"type":10,"description":32,"interventionNames":33},"RLS-0071 Expansion Cohort 1","12 participants will receive 10 mg\u002Fkg Q8H RLS-0071 for 14 days",[13],{"label":35,"type":10,"description":36,"interventionNames":37},"RLS-0071 Expansion Cohort 2","12 participants will receive 20 mg\u002Fkg Q8H RLS-0071 for 14 days",[13],[39],{"type":40,"name":41,"description":42,"armGroupLabels":43,"otherNames":44},"DRUG","RLS-0071","RLS-0071 will be administered for 7 or 14 days according to the assigned dose group.",[15,19,23,27,31,35,9],null,[46],{"name":47,"role":48,"phone":49,"phoneExt":44,"email":50},"Linda Dell, MBA","CONTACT","201-675-4044","ldell@realtals.com",[52,66,75,85,95,105,114,126,138,146,154],{"facility":53,"status":54,"city":55,"state":56,"zip":57,"country":58,"countryCode":59,"cosmosGeoPoint":60,"geoPoint":65,"contacts":44},"Site 1091","ACTIVE_NOT_RECRUITING","Duarte","California","91010","United States","US",{"type":61,"coordinates":62},"Point",[63,64],-117.97729,34.13945,{"lat":64,"lon":63},{"facility":67,"status":54,"city":68,"state":56,"zip":69,"country":58,"countryCode":59,"cosmosGeoPoint":70,"geoPoint":74,"contacts":44},"Site 1343","Los Angeles","90095",{"type":61,"coordinates":71},[72,73],-118.24368,34.05223,{"lat":73,"lon":72},{"facility":76,"status":54,"city":77,"state":78,"zip":79,"country":58,"countryCode":59,"cosmosGeoPoint":80,"geoPoint":84,"contacts":44},"Site 1318","Atlanta","Georgia","30041",{"type":61,"coordinates":81},[82,83],-84.38798,33.749,{"lat":83,"lon":82},{"facility":86,"status":54,"city":87,"state":88,"zip":89,"country":58,"countryCode":59,"cosmosGeoPoint":90,"geoPoint":94,"contacts":44},"Site 1068","St Louis","Missouri","63110",{"type":61,"coordinates":91},[92,93],-90.19789,38.62727,{"lat":93,"lon":92},{"facility":96,"status":54,"city":97,"state":98,"zip":99,"country":58,"countryCode":59,"cosmosGeoPoint":100,"geoPoint":104,"contacts":44},"Site 1100","Cincinnati","Ohio","45229",{"type":61,"coordinates":101},[102,103],-84.51439,39.12711,{"lat":103,"lon":102},{"facility":106,"status":54,"city":107,"state":98,"zip":108,"country":58,"countryCode":59,"cosmosGeoPoint":109,"geoPoint":113,"contacts":44},"Site 1382","Columbus","43210",{"type":61,"coordinates":110},[111,112],-82.99879,39.96118,{"lat":112,"lon":111},{"facility":115,"status":116,"city":117,"state":44,"zip":118,"country":119,"countryCode":120,"cosmosGeoPoint":121,"geoPoint":125,"contacts":44},"Site 3242","RECRUITING","Freiburg im Breisgau","79106","Germany","DE",{"type":61,"coordinates":122},[123,124],7.85222,47.9959,{"lat":124,"lon":123},{"facility":127,"status":116,"city":128,"state":129,"zip":130,"country":131,"countryCode":132,"cosmosGeoPoint":133,"geoPoint":137,"contacts":44},"Site 3101","Seville","SE","41013","Spain","ES",{"type":61,"coordinates":134},[135,136],-5.97317,37.38283,{"lat":136,"lon":135},{"facility":139,"status":116,"city":140,"state":44,"zip":44,"country":131,"countryCode":132,"cosmosGeoPoint":141,"geoPoint":145,"contacts":44},"Site 3360","Madrid",{"type":61,"coordinates":142},[143,144],-3.70256,40.4165,{"lat":144,"lon":143},{"facility":147,"status":116,"city":148,"state":44,"zip":44,"country":131,"countryCode":132,"cosmosGeoPoint":149,"geoPoint":153,"contacts":44},"Site 3227","Salamanca",{"type":61,"coordinates":150},[151,152],-3.67975,40.42972,{"lat":152,"lon":151},{"facility":127,"status":116,"city":128,"state":44,"zip":44,"country":131,"countryCode":132,"cosmosGeoPoint":155,"geoPoint":157,"contacts":44},{"type":61,"coordinates":156},[135,136],{"lat":136,"lon":135},{"type":159,"investigatorFullName":44,"investigatorTitle":44,"investigatorAffiliation":44,"oldNameTitle":44,"oldOrganization":44},"SPONSOR",[161],{"name":162,"class":163},"CTI Clinical Trial and Consulting Services","OTHER","100542509","phase-2-safety-pk-pd-dosing-and-efficacy-of-rls-0071for-the-treatment-of-hospitalized-patients-with-steroid-refractory-acute-graft-versus-host-disease-100542509",false,"NCT06343792","Safety, PK, PD, Dosing, and Efficacy of RLS-0071for the Treatment of Hospitalized Patients With Steroid-Refractory Acute Graft-versus-Host Disease","Phase 2 Open Label Prospective Dose-Ranging Clinical Trial With Escalation and Expansion Cohorts to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Dosing, and Efficacy of RLS-0071 for the Treatment of Hospitalized Patients With Steroid-Refractory Acute Graft-versus-Host Disease","AURORA","Inclusion Criteria:\n\n* Male or female adults or adolescents (\\>12 years old).\n* Hospitalized with steroid-refractory aGvHD (grade II-IV) after allo-HSCT\n* Anticipated hospital length-of-stay of at least 1 week from the time of RLS-0071 initiation.\n* No plans to add additional GvHD treatment medications or to add, dose-adjust, or discontinue GvHD prophylactic medications during the 7-days of RLS-0071 treatment.\n* Neutrophil recovery following the stem-cell transplantation, defined as blood neutrophil count \\>500\u002FmL for at least 3 consecutive measurements and not supported by growth factor supplementation\n* Weight ≥40 kg and ≤ 140 kg at screening.\n\nExclusion Criteria:\n\n* Has received more than 1 allo-HSCT\n* Current, previous, or planned use of any systemic treatment in addition to or other than corticosteroids or ruxolitinib for aGvHD\n* Previous failure of ruxolitinib treatment\n* Uncontrolled GI infection\n* Endoscopic and biopsy testing (if performed) that definitively rules out lower GI aGvHD\n* Chronic GvHD\n* Participants with evidence of relapsed primary disease, or participants who have been treated for relapse after the allo-HSCT was performed.\n* Unresolved toxicity or complications (other than aGvHD) due to the allo-HSCT\n* Any corticosteroid therapy for indications other than aGvHD at doses of methylprednisolone or equivalent \\>1 mg\u002Fkg per day within 7 days of enrollment.\n* Severe organ dysfunction unrelated to underlying aGvHD\n* Known hypersensitivity, allergy, or anaphylactic reaction to polyethylene glycol (PEG)\n* Significant liver disease that is unrelated to GvHD\n* Severe kidney disease\n* Currently breast feeding.\n* Known pregnancy, a positive pregnancy test at screening, or lactation for WOCBP.\n* Active hepatitis B virus (HBV) or hepatitis C virus infection that requires treatment or human immunodeficiency virus (HIV)-1 or HIV-2.\n* Active sepsis","ALL","12 Years",{"count":175,"type":176},66,"ESTIMATED","INTERVENTIONAL",[179],"PHASE2","This study is a Open Label Prospective Dose-Ranging Escalation and Expansion Trial to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Dosing, and Efficacy of RLS-0071 for the secondary treatment of acute Graft-versus-Host Disease (aGvHD) in hospitalized patients who are steroid-refractory.",[182],"Steroid Refractory GVHD","2025-11-18",{"date":185,"type":186},"2025-11-24","ACTUAL",{"date":188,"type":186},"2024-08-31",{"date":190,"type":176},"2026-12",{"name":5,"class":6},11]